Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
7.99
-0.03 (-0.37%)
At close: Sep 12, 2025, 4:00 PM EDT
7.66
-0.33 (-4.09%)
After-hours: Sep 12, 2025, 7:39 PM EDT
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $154.69M in the quarter ending June 30, 2025, with 22.12% growth. This brings the company's revenue in the last twelve months to $571.16M, up 25.35% year-over-year. In the year 2024, Amicus Therapeutics had annual revenue of $528.30M with 32.29% growth.
Revenue (ttm)
$571.16M
Revenue Growth
+25.35%
P/S Ratio
4.29
Revenue / Employee
$1,144,609
Employees
499
Market Cap
2.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
| Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
| Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
| Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
| Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
FOLD News
- 5 days ago - Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 6 days ago - New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM - GlobeNewsWire
- 16 days ago - In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful - GlobeNewsWire
- 16 days ago - Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - GlobeNewsWire
- 20 days ago - Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student - Business Wire
- 24 days ago - In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump - GlobeNewsWire
- 27 days ago - The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination - GlobeNewsWire
- 6 weeks ago - Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200 - Seeking Alpha